Proactive Investors - Run By Investors For Investors

THC Global to exclusively import CBD products into New Zealand

THC Global has expanded into New Zealand's medicinal cannabis market.
map of new zealand
Endoca’s unique CBD and CBD+CBDa products will be imported into New Zealand

THC Global Group Ltd (ASX:THC) has secured exclusive rights to import Endoca’s cannabidiol (CBD) products from Europe into New Zealand.

Furthermore, it has established a supply chain to patients through a strategic partnership with DATAPHARM.

THC Global has been advised by Endoca that they have received strong interest from over a thousand patients in New Zealand seeking their product.

READ: THC Global Group completes name change from The Hydroponics Company Ltd

THC Global’s CEO Ken Charteris said: “We look forward to our first orders in New Zealand in the coming weeks as we continue to expand our global footprint in the medicinal cannabis market, both in the Asia Pacific and in North America.

“The expansion into New Zealand represents the next step in the development of THC Global as a significant participant in the global medicinal cannabis market.”

Other cannabis-based medicine costs $14,000 per year

The only other MedSafe approved cannabis-based medication in New Zealand currently costs patients $14,000 per year.

THC Global anticipates supplying Endoca CBD products to New Zealand patients at a substantially lower price, addressing a major barrier to patient uptake, and increasing accessibility for patients.

Favourable regulatory conditions to support revenue growth

THC Global has identified New Zealand as an attractive market due to favourable regulatory conditions.

New Zealand regulations allow products with over 98% CBD such as the Endoca range to be prescribed by medical practitioners including GPs without the need for special authorisation as is required in Australia.

The company expects that this will result in rapid revenue generating sales as the company commences supply to patients in New Zealand.

The company’s operating subsidiary in New Zealand, THC Pharma (NZ) Limited will commence importing once permits are received, which are being sort on an expedited basis.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
man with erectile dysfunction
April 27 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use